Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/16/2024 | Outperform | Macquarie | |
9/26/2024 | $8.00 → $14.00 | Hold → Buy | Jefferies |
6/7/2024 | $8.00 | Sell → Hold | Deutsche Bank |
2/23/2022 | $32.00 → $31.00 | Outperform | Credit Suisse |
12/22/2021 | $33.00 → $32.00 | Outperform | Credit Suisse |
11/4/2021 | $29.00 → $27.00 | Market Perform | SVB Leerink |
9/27/2021 | $29.00 | Market Perform | SVB Leerink |
8/9/2021 | $30.00 → $32.00 | Neutral | Mizuho |
Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, August 5, 2025 at 9:00 a.m. ET to discuss results from operations for the quarter ended June 30, 2025. A detailed press release will be issued the morning of August 5, 2025 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and childre
Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today announced that its board of directors has appointed Kurt D. Newman, M.D., former President and Chief Executive Officer of Children's National Hospital in Washington, D.C. and Professor Emeritus of Surgery and Pediatrics at George Washington University School of Medicine and Health Sciences, as an independent director, effective July 1, 2025. Dr. Newman, a surgeon and nationally recognized leader in pediatric healthcare and a long-term healthcare executive, served as President and Chief Executive Officer of Children's National Hospital for 12 years, after spending over 25 years there as a pediatric sur
Raises Full Year 2025 Adjusted EBITDA Outlook Range Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.24 per share for the three months ended March 31, 2025. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.33. For the 2025 first quarter, Pediatrix reported the following results: Net revenue of $458 million; Net income of $21 million; and Adjusted EBITDA of $49 million. "Our strong first quarter results reflect same-unit top-line outperformance versus our expectations, continued steady cost management and the successful results of the portfolio restructuring we completed last year. As a result of our strong f